Human PD - L1 inhibitor III

Description:

PD-1 (Programed cell death protein 1) is a cell surface receptor. PD-1 and its ligand PD-L1 are crucial immune checkpoints to downregulate T cell activation, tolerance and immunopathology. Developing inhibitors specifically blocking the PD-1/PD-L1 pathway has become a popular approach toward cancer treatment

Sequence:

TEKDYRHGNIRMKLAYDL

General

References

Comments (0)

Name	Human PD - L1 inhibitor III
Category	Cancer Research Peptides
One Letter Code	TEKDYRHGNIRMKLAYDL
Three Letter Code	{Thr}{Glu}{Lys}{Asp}{Tyr}{Arg}{His}{Gly}{Asn}{Ile}{Arg}{Met}{Lys}{Leu}{Ala}{Tyr}{Asp}{Leu}
Molecular Weight	2223.700
Application	Cancer Research

Bardhan, Kankana, Theodora Anagnostou, and Vassiliki A. Boussiotis. "The PD1: PD-L1/2 pathway from discovery to clinical implementation." Frontiers in immunology 7 (2016): 550.

Li, Qiao, et al. "Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor." Oncotarget 7.40 (2016): 64967.

D’Errico, Gabriele, Heather L. Machado, and Bruno Sainz. "A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet." Clinical and translational medicine 6.1 (2017): 1-10.